Search results
Spinal Muscular Atrophy (SMA): New Treatments Offer Hope
TODAY via Yahoo News· 2 years agoAt her eight-month pregnancy check-up, Lizmara Figueroa met with a new doctor. As he walked out the...
What to Know About Spinal Muscular Atrophy (SMA)
Verywell Health via Yahoo News· 9 months agoNew treatments have improved outlookMedically reviewed by Nicholas R. Metrus, MD Spinal muscular atrophy (SMA) is a genetic disease that causes muscle...
Twin 'was just melting': Babies with neuromuscular disease find new hope in Austin
Austin American-Statesman via Yahoo News· 1 year agoJenny and Jarod Carter's twins weren't making their typical infant milestones after they were born...
Biohaven (BHVN) Begins Phase III Study on SMA Candidate
Zacks via Yahoo Finance· 2 years agoBiohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted...
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
Zacks via Yahoo Finance· 9 months agoRoche RHHBY announced that the European Commission (“EC”) had approved the label expansion for...
Most babies with this rare genetic disease are on ventilators by 8 months. This Austin baby beat the...
Austin American-Statesman via Yahoo News· 1 year agoNoah Strauch loves to laugh. He loves to put things into a bucket and dump them out again. He crawls...
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Zacks via Yahoo Finance· 1 month agoIonis Pharmaceuticals IONS reported a loss of 98 cents per share for first-quarter 2024, which was...
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
Zacks via Yahoo Finance· 10 months agoIonis Pharmaceuticals IONS reported a loss of 60 cents per share for second-quarter 2023, which was...
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Benzinga via Yahoo Finance· 2 years agoRoche Holdings AG (OTC: RHHBY) announced new two-year data from the JEWELFISH study evaluating...
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
Zacks via Yahoo Finance· 2 years agoIonis Pharmaceuticals IONS reported a loss of 33 cents per share in third-quarter 2022, narrower...
